Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system

References

• WHO [Internet]. Burden and mortality of COPD. Geneva (Switzerland): World Health Organization; c2018 [cited 2018 May 04]. Available from: http://www.who.int/respiratory/copd/en/.
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017; c2018 [cited 2018 May 04]. Available from: http://www.goldcopd.org.
   Google Scholar
• GOLD (Global Initiative for Chronic Obstructive Lung Disease) [Internet]. Global strategy for the diagnosis, management, and prevention of COPD. 2017 [cited 2018 May 29]. Available from: http://goldcopd.org/download/326/.
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Chong J, Poole P, Leung B, et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (review). Cochrane Database Syst Rev. 2011 [cited 2018 May 04];5:CD002309. DOI:10.1002/14651858.CD002309.pub3
   Web of Science ®Google Scholar
• Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 [cited 2018 May 29];9:CD002309. DOI:10.1002/14651858.CD002309.pub5
   PubMed Web of Science ®Google Scholar
• Cupurdija V. Economic impact of leading prosperity diseases: COPD in South East Europe. Front Public Health. 2015 [cited 2018 May 04];3:50. DOI: 10.3389/fpubh.2015.00050
   PubMed Web of Science ®Google Scholar
• Kamusheva M, Dimitrova M, Van Boven JFM, et al. Clinical characteristics, treatment patterns and socio-economic burden of COPD in Bulgaria. J Med Econ. 2017;20(5):503–509.
   PubMed Web of Science ®Google Scholar
• Pavlov P, Ivanov Y, Glogovska P, et al. New epidemiology data on COPD in the Pleven region. Thoracic Med. 2012;2(IV):44–50.
   Google Scholar
• Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013 [cited 2018 May 04];13:26. DOI:10.1186/1471-2466-13-26
   PubMed Web of Science ®Google Scholar
• Geake JB, Dabscheck EJ, Wood-Baker R, et al. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 [cited 2018 May 04];1:CD010139. DOI: 10.1002/14651858.CD010139.pub2
   PubMed Web of Science ®Google Scholar
• Rootmensen GN, van Keimpema AR, Jansen HM et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23(5):323–328.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343.
   PubMed Web of Science ®Google Scholar
• Dahl R, Jadayel D, Alagappan VK, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013;8:501–508.
   PubMed Web of Science ®Google Scholar
• Wedzicha J, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
   PubMed Web of Science ®Google Scholar
• D`Urzo A, Rennard S, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week randomized, placebo-controlled AUGMENT-COPD study. Respir Res. 2014 [cited 2018 May 04];15:123. DOI: 10.1186/s12931-014-0123-0
   PubMed Web of Science ®Google Scholar
• National Health Insurance Fund in Bulgaria [Internet]. Official website. Available from: https://www.nhif.bg/
   Google Scholar
• National Council on Pricing and Reimbursement [Internet]. Positive Drug List. Annex 1. Available from: http://portal.ncpr.bg/registers/pages/register/list-medicament.xhtml
   Google Scholar
• National Health Insurance Fund [Internet]. National framework contract. Available from: https://www.nhif.bg/get_file?section=document&uuid=504f49c1-397e-49c2-b478-2c7c49504386
   Google Scholar
• WHO [Internet]. Introduction to drug utilization research. World Health Organization. Geneva Switzerland: WHO; 2003 [cited 2018 May 04]. Available from: https://www.whocc.no/filearchive/publications/drug_utilization_research.pdf
   Google Scholar
• Tachkov K, Kamusheva M, Pencheva V, et al. Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD). Biotechnol Biotechnol Equip. 2017;31(4):855–861.
   Web of Science ®Google Scholar
• Papaioannou A, Bania E, Alexopoulos E, et al. Sex discrepancies in COPD patients and burden of the disease in females: a nationwide study in Greece (Greek Obstructive Lung Disease epidemiology and health economics: GOLDEN study). Int J Chron Obstruct Pulmon Dis. 2014;9:203–213.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med. 2003;2:67–74.
   PubMedGoogle Scholar
• Kiri VA, Bettoncelli G, Testi R, et al. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med. 2005;99:1115–1124.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922.
   PubMed Web of Science ®Google Scholar
• Jeetvan GP, Saurabh PN, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014;9:289–300.
   PubMed Web of Science ®Google Scholar
• Geitona M, Hatzikou M, Steiropoulos P, et al. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med. 2011;105(3):402–409.
   PubMed Web of Science ®Google Scholar
• Simoens S. Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review. J Eval Clin Pract. 2013;19:1004–1011.
   PubMed Web of Science ®Google Scholar
• Alexopoulos E, Foteini M, Mitsiki E, et al. Frequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health economics: GOLDEN study. Int J Chron Obstruct Pulmon Dis. 2015;10:2665–2674.
   PubMed Web of Science ®Google Scholar